UNSPSC 51182701: Glimepiride/pioglitazone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182701 Glimepiride/pioglitazone is a Commodity code, yet the recent state and local procurement activity tagged under it does not reflect pharmaceutical procurement. Seminole County, Florida posted an IFB on June 30, 2026, for naloxone and drug deactivation systems—emergency response and harm-reduction supplies, not diabetes medications. The mismatch between the code's nominal scope (a specific antidiabetic drug combination) and the actual solicitation signals either a coding error in the county's procurement system or a tagging misalignment that does not reflect genuine demand for products within the Glimepiride/pioglitazone category among state and local buyers.

The single recent opportunity on record—Seminole County's naloxone and safe drug deactivation systems procurement, due July 26, 2023, with quarterly delivery to the Seminole County Community Health Building in Sanford, Florida—represents harm-reduction purchasing rather than pharmaceutical inventory management. Vendors responding to that IFB were required to meet E-Verify compliance, drug-free workplace certification, and federal compliance standards tied to potential FEMA funding. The code shows no corroborating state or local opportunities for the Glimepiride/pioglitazone combination itself across other jurisdictions or states. Without evidence of active state or local demand for this specific drug formulation, pursuing the code represents a low-priority opportunity; the recent activity is unrelated to the code's stated product scope.